Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,172 GBX | -0.60% | -0.75% | +14.83% |
May. 15 | ASTRAZENECA : UBS reiterates its Sell rating | ZD |
May. 14 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
ETFs positioned on AstraZeneca PLC
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
9.20% | 11 M€ | +0.83% | - | |
5.39% | 200 M€ | +17.94% | ||
5.17% | 17 M€ | +7.97% | - | |
4.89% | 693 M€ | +13.15% | ||
4.11% | 88 M€ | +10.37% | - | |
3.47% | 232 M€ | +13.93% | ||
2.74% | 4 M€ | -.--% | - | |
2.57% | 6 M€ | -.--% | ||
2.53% | 7 M€ | 0.00% | - | |
2.53% | 664 M€ | +11.13% | ||
1.54% | 29 M€ | +8.37% | - | |
1.51% | 2 M€ | -.--% | - | |
1.51% | 2 M€ | +9.19% | - | |
1.26% | 12 M€ | +15.09% | - | |
1.19% | 48 M€ | +10.46% | ||
1.16% | 10 M€ | -3.35% | - | |
0.97% | 7 M€ | +6.66% | - | |
0.89% | 32 M€ | +8.96% | - | |
0.86% | 276 M€ | +11.40% | - | |
0.70% | 264 M€ | -.--% | - | |
0.69% | 187 M€ | +9.41% | - | |
0.69% | 477 M€ | +12.35% | ||
0.57% | 205 M€ | -.--% | ||
0.54% | 284 M€ | -.--% | ||
0.51% | 23 M€ | -.--% | - | |
0.51% | 786 M€ | -.--% | ||
0.50% | 206 M€ | -.--% | ||
0.48% | 727 M€ | +9.25% | ||
0.43% | 283 M€ | +19.68% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.83% | 239B | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B | |
+0.89% | 124B |
- Stock Market
- Equities
- AZN Stock
- Funds and ETFs AstraZeneca PLC